Learn Before
Relation
Vaccine Safety Results Details
- The 45 enrolled participants received their first vaccination between 3/16/20-4/14/20
- 3 participants did not receive the second vaccination: one participant in the 25-ug group developed urticaria on both legs 5 days after the first dose, and two participants were in quarantine due to suspected COVID-19.
- Otherwise, no serious adverse events were noted.
- Solicited systemic adverse events were reported by 33% of the 25-uL group, 67% of the 100-uL group, and 53% of the 250-uL group after the first vaccination. -After the second, 54%, 100%, and 100% of participants experienced systemic adverse events after the second vaccination respectively. In the 250-uL group, 3 participants reported one or more severe events.
- As far as fevers went, after the first vaccination, none of the participants had a fever. After the second, 0% experienced a fever from the 25-uL group, 40% in the 100-uL group, and 57% in the 250-uL group. One of the participants in the last group was noted to have a severe fever (39.6 degrees Celsius).
- Pain at the injection site was common
- Adverse events in over 50% of patients: fatigue, chills, headache, and myalgia.
0
1
Updated 2020-10-18
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences